ClinicalTrials.gg
CompletedNCT03834753Updated Aug 3, 2026Results posted

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of bevacizumab and ranibizumab in Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 50 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Primary conditionWet Macular DegenerationRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Wet Macular Degeneration
Why
  1. The study's listed conditions name Wet Macular Degeneration, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.

Enrollment
17th of 45
228 · median 91
Started
2019
with 9 others
Phase 3
13 of 49
1 open now
Registered
23rd of 49
by date
Lead sponsor
4 of 49
Outlook Therapeutics, Inc.

Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 17th largest by enrollment of the 45 interventional ones that give a count, is one of 10 that started in 2019, is one of 13 in phase 3, and was the 23rd registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Wet Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

03

Conditions studied

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration

Browse trials for

Keywords

  • Subfoveal Choroidal Neovascularization
04

In context

Wet Macular Degeneration Reclassified

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 228 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye
  • Best corrected visual acuity of 25-67 letters read (20/50 to 20/320 Snellen equivalent)
  • Study eye must:

    • Have active leakage on Fluorescein Angiogram involving the fovea
    • Have edema involving the fovea
    • Be free of scarring, fibrosis, or atrophy involving the central foveal zone

Exclusion criteria

Exclusion Criteria:

  • Previous subfoveal focal laser photocoagulation in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
  • Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year
  • Active intraocular inflammation (grade trace or above) in the study eye
  • Current vitreous haemorrhage in the study eye
  • Polypoidal choroidal vasculopathy (PCV) in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
  • Premenopausal women not using adequate
  • Current treatment for active systemic infection
  • Known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    bevacizumab

    ONS-5010

    Biological: bevacizumab

  • Active comparator
    ranibizumab

    Biological: ranibizumab

Interventions

  • Biologicalbevacizumab

    1.25 mg, intravitreal injection

    Also known as: ONS-5010

  • Biologicalranibizumab

    0.5mg, intravitreal injection

07

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)

    BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.

    Time frame: 11 months

Secondary outcomes

  1. Mean Change in the Best Corrected Visual Acuity

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: 11 months

  2. Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: 11 months

  3. Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity

    BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

    Time frame: 11 months

  4. Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity

    BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.

    Time frame: 11 months

  5. Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse

    Time frame: 11 months

08

Results

Posted Aug 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneBevacizumabRanibizumab
Started113115
Completed10395
Not completed1020

Outcome measures

PrimaryProportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)

BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.

Time frame:
11 months
Reported as:
Count of participants · Participants
Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)
ParticipantsBevacizumabRanibizumab
Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)4524
SecondaryMean Change in the Best Corrected Visual Acuity

BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

Time frame:
11 months
Reported as:
Mean · letters
Mean Change in the Best Corrected Visual Acuity
lettersBevacizumabRanibizumab
Mean Change in the Best Corrected Visual Acuity11.2 ± 12.195.8 ± 14.80
SecondaryProportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity

BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

Time frame:
11 months
Reported as:
Count of participants · Participants
Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity
ParticipantsBevacizumabRanibizumab
Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity6136
SecondaryProportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity

BCVA to be assessed as letters read using the ETDRS charts. A positive change represents an improvement in visual acuity.

Time frame:
11 months
Reported as:
Count of participants · Participants
Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity
ParticipantsBevacizumabRanibizumab
Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity7453
SecondaryProportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity

BCVA to be assessed as letters read using the ETDRS charts. A negative change represents a decrease in visual acuity.

Time frame:
11 months
Reported as:
Count of participants · Participants
Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity
ParticipantsBevacizumabRanibizumab
Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity10186
SecondaryProportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse
Time frame:
11 months
Reported as:
Count of participants · Participants
Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse
ParticipantsBevacizumabRanibizumab
Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse1425

Adverse events

Collected over from enrollment to 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab3/113 (2.7%)14/113 (12.4%)31/113 (27.4%)
Ranibizumab2/115 (1.7%)16/115 (13.9%)34/115 (29.6%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventBevacizumabRanibizumab
Acute myocardial infarctionCardiac disorders1/1130/115
Aortic valve stenosisCardiac disorders1/1130/115
Bundle branch blockCardiac disorders1/1130/115
Myocardial infarctionCardiac disorders1/1130/115
DeathGeneral disorders1/1130/115
COVID-19Infections and infestations1/1131/115
Clostridium difficile infectionInfections and infestations1/1130/115
PneumoniaInfections and infestations1/1130/115
Urinary tract infectionInfections and infestations1/1130/115
Rib fractureInjury, poisoning and procedural complications1/1130/115
Most frequent other events
Most frequent other events
EventBevacizumabRanibizumab
Visual acuity reducedEye disorders3/11317/115
Conjunctival haemorrhageEye disorders10/1133/115
Urinary tract infectionInfections and infestations8/1135/115
Retinal haemorrhageEye disorders3/1138/115
Intraocular pressure increasedInvestigations7/1131/115

Baseline characteristics

Age, Continuous
Age, Continuous(years)BevacizumabRanibizumabTotal
Mean78.8 ± 8.3079.1 ± 8.4978.9 ± 8.38
Sex: Female, Male
Sex: Female, Male(Participants)BevacizumabRanibizumabTotal
Female6769136
Male464692
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BevacizumabRanibizumabTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American202
White110113223
More than one race000
Unknown or Not Reported011
09

Study locations

50 sites
  • Clinical Site
    Tucson, Arizona 85710, United States
  • Clinical Site
    Arcadia, California 91007, United States
  • Clinical Site
    Beverly Hills, California 90211, United States
  • Clinical Site
    Campbell, California 95008, United States
  • Clinical Site
    Glendale, California 91203, United States
  • Clinical Site
    Laguna Hills, California 92653, United States
  • Clinical Site
    Long Beach, California 90807, United States
  • Clinical Site
    Mountain View, California 94040, United States
  • Clinical Site
    Oxnard, California 93036, United States
  • Clinical Site
    Palm Desert, California 92260, United States
  • Clinical Site
    Poway, California 92064, United States
  • Clinical Site
    Sacramento, California 95841, United States
  • Clinical Site
    Santa Maria, California 93454, United States
  • Clinical Site
    Tustin, California 92780, United States
  • Clinical Site
    Golden, Colorado 80401, United States
  • Clinical Site
    Hamden, Connecticut 06518, United States
  • Clinical Site
    Clearwater, Florida 33761, United States
  • Clinical Site
    Pinellas Park, Florida 33782, United States
  • Clinical Site
    Sarasota, Florida 24233, United States
  • Clinical Site
    Winter Haven, Florida 33880, United States
  • Clinical Site
    Augusta, Georgia 30909, United States
  • Clinical Site
    Marietta, Georgia 30060, United States
  • Clinical Site
    Downers Grove, Illinois 60615, United States
  • Clinical Site
    Lemont, Illinois 60439, United States
  • Clinical Site
    Springfield, Illinois 62704, United States
  • Clinical Site
    Indianapolis, Indiana 46290, United States
  • Clinical Site
    Hagerstown, Maryland 21740, United States
  • Clinical Site
    Edina, Minnesota 55435, United States
  • Clinical Site
    St Louis, Missouri 63144, United States
  • Clinical Site
    Bloomfield, New Jersey 07003, United States
  • Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Clinical Site
    New York, New York 10021, United States
  • Clinical Site
    Chambersburg, Pennsylvania 17201, United States
  • Clinical Site
    Monroeville, Pennsylvania 15146, United States
  • Clinical Site
    Rapid City, South Dakota 57701, United States
  • Clinical Site
    Germantown, Tennessee 38138, United States
  • Clinical Site
    Abilene, Texas 79606, United States
  • Clinical Site
    Amarillo, Texas 79106, United States
  • Clinical Site
    Arlington, Texas 76012, United States
  • Clinical Site
    Dallas, Texas 75231, United States
  • Clinical Site
    Grapevine, Texas 76051, United States
  • Clinical Site
    Houston, Texas 77030, United States
  • Clinical Site
    McAllen, Texas 78503, United States
  • Clinical Site
    San Antonio, Texas 78240, United States
  • Clinical Site
    San Antonio, Texas 78251, United States
  • Clinical Site
    The Woodlands, Texas 77384, United States
  • Clinical Site
    Willow Park, Texas 76807, United States
  • Clinical Site
    Salt Lake City, Utah 84107, United States
  • Clinical Site
    Norfolk, Virginia 23502, United States
  • Clinical Site
    Madison, Wisconsin 53705, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data will not be shared until all global regulatory filings are complete.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jun 2021, 23 months.

Results were first posted in Aug 2026, 5 years 1 month after primary completion. A results delay was requested in Nov 2021.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 8, 2019
StartActual
Jun 25, 2019
Primary completionActual
Jun 7, 2021
CompletionActual
Jul 8, 2021
Results delay requested
Nov 16, 2021
Results first posted
Aug 3, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03834753
Lead sponsor
Outlook Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 8, 2019
Start date
Jun 25, 2019
Primary completion
Jun 7, 2021
Completion
Jul 8, 2021
Results posted
Aug 3, 2026
Last update
Aug 3, 2026

Study contacts

Jennifer M Kissner, PhD
study director · Outlook Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion